20/20 Biolabs, Inc.
No SEC Form 4 filings for $AIDX in the last 30 days.
See all $AIDX insider activity →20/20 BioLabs (AIDX) reported Q2 2026 revenue up 36.5% to $0.7M. OneTest revenue rose 47.1% to $0.7M and was 95.3% of total revenue. Gross margin increased to 41.7% from 30.5%. Operating expenses rose to $1.5M; net loss widened to $1.5M ($0.26/share). Cash was $4.5M at June 30, 2026.
20/20 Biolabs, Inc. (AIDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030215301ex99-1.htm PRESS RELEASE ISSUED ON AUGUST 17, 2026 Exhibit 99.1 20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level Total Revenue Increased 37% to $0.7 Million and
20/20 Biolabs, Inc. (AIDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ea029890701ex10-1.htm STANDSTILL AGREEMENT, DATED JULY 16, 2026, BETWEEN STREETERVILLE CAPITAL, LLC AND 20/20 BIOLABS, INC Exhibit 10.1 STANDSTILL AGREEMENT This Standstill Agreement (this “ Agreement ”) is entered into as of July 16, 2026 (the “ Effective Date ”) by an
Over the past 7 days, alphai's AI scored 2 news stories mentioning AIDX (20/20 Biolabs, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent AIDX coverage spans financial news, earnings and corporate actions.
The print shows accelerating OneTest revenue concentration and improving unit economics, but losses widened and cash remains modest.
The 8-K provides fresh operating and balance-sheet datapoints plus financing overhang updates (convertible notes eliminated, 120-day standstill).
The standstill can reduce near-term dilution/overhang from preferred conversions, but it also preserves Investor’s conversion rights after the period or upon breach.
The webinar is a forward-looking reimbursement and evidence-generation pitch, plus a preliminary Q2 revenue expectation, which can move near-term sentiment but lacks audited confirmation.
20/20 BioLabs (AIDX) reports significant financial improvements in 2025, including a 17% revenue increase and reduced net loss, driven by higher-margin revenue streams and decreased operating expenses. The company's positive financial trajectory, along with secured funding and upcoming growth initiatives, suggests potential for stock appreciation.
alphai scores every news story that mentions AIDX with an AI model for sentiment and relevance, and aggregates insider trades from 20/20 Biolabs, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
20/20 BioLabs (AIDX) reported Q2 2026 revenue up 36.5% to $0.7M. OneTest revenue rose 47.1% to $0.7M and was 95.3% of total revenue. Gross margin increased to 41.7% from 30.5%. Operating expenses rose to $1.5M; net loss widened to $1.5M ($0.26/share). Cash was $4.5M at June 30, 2026.
5 min read20/20 Biolabs, Inc. (AIDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030215301ex99-1.htm PRESS RELEASE ISSUED ON AUGUST 17, 2026 Exhibit 99.1 20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level Total Revenue Increased 37% to $0.7 Million and
6 min read20/20 Biolabs, Inc. (AIDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ea029890701ex10-1.htm STANDSTILL AGREEMENT, DATED JULY 16, 2026, BETWEEN STREETERVILLE CAPITAL, LLC AND 20/20 BIOLABS, INC Exhibit 10.1 STANDSTILL AGREEMENT This Standstill Agreement (this “ Agreement ”) is entered into as of July 16, 2026 (the “ Effective Date ”) by an
3 min read20/20 BioLabs (Nasdaq: AIDX) discussed in an investor webinar its OneTest for Cancer strategy for potential Medicare coverage of FDA-authorized MCED blood tests starting in 2028. The company said OneTest uses protein biomarkers and serial tracking, not ctDNA-only. It expects Q2 MCED revenue to be its highest, at least 30% above Q2 2025, based on preliminary figures.
5 min read20/20 BioLabs (AIDX) reported a 17% increase in 2025 revenue to $2.0 million, with significant improvement in gross margin to 29.6% and a 33% reduction in net loss to $3.7 million. This financial improvement was driven by a shift to higher-margin revenue streams and decreased operating expenses. The company also secured a $5.0 million tranche under a potential $40 million preferred purchase agreement and highlighted future growth drivers like a state-funded firefighter cancer screening program and the launch of OneTest for Longevity.
4 min read20/20 Biolabs reported fiscal-year revenue of $2.045 million, a 16.7% increase, driven by higher OneTest and CLIAx sales and a shift to a premium test mix. The company recorded a net loss of $(3.739) million, an improvement of 32.7% versus the prior year, with gross profit increasing to $0.605 million. Operational developments include the launch of OneTest for Longevity and expansion into multi-cancer screenings for veterans.
2 min readThis article lists 12 healthcare stocks that experienced significant movement during Monday's intraday trading session. It highlights several gainers, including Arcellx (NASDAQ: ACLX) and Vanda Pharmaceuticals (NASDAQ: VNDA), and several decliners such as Gossamer Bio (NASDAQ: GOSS) and 20/20 Biolabs (NASDAQ: AIDX), along with their respective percentage changes and market caps.
4 min read
